KLOW
Research Use Only | Not for Human Consumption
A four-peptide research blend of GHK-Cu, BPC-157, TB-500, and KPV supplied in lyophilized form.
KLOW is a multi-peptide research blend for studying tissue remodeling, cellular migration, collagen synthesis, and anti-inflammatory signaling pathways in vitro. It builds on the GLOW three-peptide combination—GHK-Cu, BPC-157, and TB-500—by adding KPV, the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH, to enable parallel investigation of extracellular matrix mechanisms and melanocortin-related signaling.
Blend Components
| Component | CAS# | Formula | Molar Mass |
|---|---|---|---|
| GHK-Cu | 49557-75-7 | C₁₄H₂₂CuN₆O₄ | 401.91 g/mol |
| BPC-157 | 137525-51-0 | C₆₂H₉₈N₁₆O₂₂ | 1419.55 g/mol |
| TB-500 | 77591-33-4 | C₂₁₂H₃₅₀N₅₆O₇₈S | 4963.44 g/mol |
| KPV | 67727-97-3 | C₁₆H₃₀N₄O₄ | 342.43 g/mol |
All products are shipped in lyophilized form and must be reconstituted for in-vitro research applications. Refer to the Certificate of Analysis for purity and identity specifications.
Four-peptide research blend for tissue and cellular research applications
What is KLOW?
KLOW assembles four peptides that each entered the research literature along separate paths. GHK-Cu, a copper-binding tripeptide, was first described by Loren Pickart in the 1970s and has since been examined in vitro for associations with gene-expression and matrix-remodeling pathways. BPC-157 emerged in the early 1990s from Croatian researchers studying gastric protective fractions, while TB-500 (Thymosin Beta-4) traces to Allan Goldstein's thymosin work at the National Institutes of Health in the 1960s.
The fourth component, KPV, is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (alpha-MSH). It has been investigated in preclinical research for anti-inflammatory and melanocortin-related signaling pathways, including studies of intestinal epithelial cell models. KPV is what distinguishes KLOW from the three-peptide GLOW blend: KLOW pairs GLOW's extracellular-matrix-focused peptides with an additional tripeptide studied for distinct inflammatory-signaling mechanisms.
Combining the four peptides lets researchers examine complementary in-vitro mechanisms—matrix and collagen signaling, angiogenesis, cellular migration, and melanocortin-related inflammatory pathways—within a single lyophilized preparation. This product is intended for research use only.
What is KLOW studied for?
The following research areas represent documented studies available in the scientific literature. We make no claims regarding the benefits, efficacy, or therapeutic applications of this product.
Extracellular Matrix & Collagen-Synthesis Research
Research investigating GHK-Cu, BPC-157, and TB-500 associations with extracellular matrix components and collagen synthesis pathways in vitro
Preclinical Dermal-Model Research
Preclinical dermal-model studies examining blend associations with fibroblast and keratinocyte activity in laboratory models
Angiogenesis & Cellular Migration Research
Research on new blood vessel formation and cell migration pathways relevant to tissue-repair models in vitro
Anti-Inflammatory & Melanocortin-Signaling Research
Studies investigating KPV and the blend components in anti-inflammatory and melanocortin-related signaling pathways in laboratory models
How should KLOW be stored?
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability.
After reconstitution, the peptides will remain stable for up to 30 days.
Certificate of Analysis
All KLOW batches are independently tested by a third-party laboratory for purity and identity verification via HPLC with UV detection coupled with Mass Spectrometry.
HPLC Purity
—
No Certificate of Analysis is available for the selected size yet. Contact support for batch-specific documentation.
COA documents are updated with each new batch. Contact support for batch-specific documentation.
Clinical References
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108.
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51.
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
Related products
-
BPC-157
$55.00 -
BPC-157 + TB-500
$115.00 -
CJC-1295 + Ipamorelin
$85.00 -
GHK-CU
$70.00 -
GLOW
$150.00






